Time-Dependent Thrombus Resolution After Tissue-Type Plasminogen Activator in Patients With Stroke and Mice

Background and Purpose— We investigated the relationship between the degree of thrombus resolution and the time from stroke onset or thrombus formation to intravenous tissue-type plasminogen activator (tPA) treatment. Methods— In patients with stroke, we measured thrombus volume on thin-section noncontrast brain computed tomographic scans taken at baseline and 1 hour after tPA administration. We determined the association between the time from symptom onset to tPA treatment and the degree of thrombus resolution. In a C57/BL6 mouse model of FeCl3-induced carotid artery thrombosis, we investigated the effect of tPA administered at different time intervals after thrombus formation, using Doppler-based blood flow measurement. Results— Of 249 patients enrolled, 171 showed thrombus on baseline computed tomography. Thrombus was resolved by ≥50% in 43 patients (25.1%, good volume reduction) and by <50% in 94 patients (55.0%, moderate volume reduction) 1 hour after tPA treatment. In 34 patients (19.9%, nonvolume reduction; either no change or thrombus volume increased), overall thrombus volume increased. The probability of thrombus resolution decreased as the time interval from symptom onset to treatment increased. On multivariate analysis, good volume reduction was independently related with shorter time intervals from symptom onset to tPA treatment (odds ratio, 0.986 per minute saved; 95% confidence interval, 0.974–0.999). In the mouse model, as the interval between thrombus formation and tPA treatment increased, the initiation of recanalization was delayed (P=0.006) and the frequency of final recanalization decreased (P for trends=0.006). Conclusions— Early administration of tPA after stroke onset is associated with better thrombus resolution.

[1]  P. Sandercock,et al.  Sensitivity and Specificity of the Hyperdense Artery Sign for Arterial Obstruction in Acute Ischemic Stroke , 2015, Stroke.

[2]  C. Molina,et al.  Impact of Time to Treatment on Tissue-Type Plasminogen Activator–Induced Recanalization in Acute Ischemic Stroke , 2014, Stroke.

[3]  Geoffrey A. Donnan,et al.  Stroke Thrombolysis: Save a Minute, Save a Day , 2014, Stroke.

[4]  A. Demchuk,et al.  Alberta Stroke Program Early Computed Tomography Score to Select Patients for Endovascular Treatment: Interventional Management of Stroke (IMS)-III Trial , 2014, Stroke.

[5]  Sung-Yu Hong,et al.  Thrombolytic Effects of the Snake Venom Disintegrin Saxatilin Determined by Novel Assessment Methods: A FeCl3-Induced Thrombosis Model in Mice , 2013, PloS one.

[6]  A. Bivard,et al.  Review of Stroke Thrombolytics , 2013, Journal of stroke.

[7]  R. Nogueira,et al.  Should clot composition affect choice of endovascular therapy? , 2012, Neurology.

[8]  Jinkwon Kim,et al.  Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging , 2012, Thrombosis and Haemostasis.

[9]  Anetta Undas,et al.  Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[10]  N. Salamon,et al.  CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke , 2011, Stroke.

[11]  K. Tenekedjiev,et al.  Hindered dissolution of fibrin formed under mechanical stress , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  M. Freund,et al.  Mechanisms underlying FeCl3‐induced arterial thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[13]  J. Weisel,et al.  Composition of coronary thrombus in acute myocardial infarction. , 2011, Journal of the American College of Cardiology.

[14]  D. Margosan,et al.  Acute cigarette smoke exposure reduces clot lysis--association between altered fibrin architecture and the response to t-PA. , 2010, Thrombosis research.

[15]  L. Schwamm,et al.  Endovascular Approaches to Acute Stroke, Part 1: Drugs, Devices, and Data , 2009, American Journal of Neuroradiology.

[16]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[17]  S. Habara,et al.  Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. , 2007, European heart journal.

[18]  Alisa S Wolberg,et al.  Thrombin generation and fibrin clot structure. , 2007, Blood reviews.

[19]  Jeffrey L Saver,et al.  The Impact of Recanalization on Ischemic Stroke Outcome: A Meta-Analysis , 2007, Stroke.

[20]  D. I. Kim,et al.  Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT , 2006, Neurology.

[21]  J. Weisel,et al.  Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Dong Joon Kim,et al.  Detection of Thrombus in Acute Ischemic Stroke: Value of Thin-Section Noncontrast-Computed Tomography , 2005, Stroke.

[23]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[24]  T. Walter,et al.  Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis. , 2004, Drugs under experimental and clinical research.

[25]  Dong Ik Kim,et al.  Immediate reocclusion following a successful thrombolysis in acute stroke: A pilot study , 2003, Neurology.

[26]  F. Netter,et al.  Supplemental References , 2002, We Came Naked and Barefoot.

[27]  M. Hoehn,et al.  Thrombolytic Treatment of Clot Embolism in Rat: Comparison of Intra-arterial and Intravenous Application of Recombinant Tissue Plasminogen Activator , 2002, Stroke.

[28]  A. Alexandrov,et al.  Speed of Intracranial Clot Lysis With Intravenous Tissue Plasminogen Activator Therapy: Sonographic Classification and Short-Term Improvement , 2001, Circulation.

[29]  A. Alexandrov,et al.  Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. , 2000, Stroke.

[30]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[31]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[32]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[33]  J. Weisel,et al.  Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. , 1992, Biophysical journal.

[34]  B. Coller Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.

[35]  J. May,et al.  Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. , 1989, Circulation.

[36]  V. Menys,et al.  The kinetics of platelet and fibrin deposition on to damaged rabbit carotid arteries in vivo: involvement of platelets in the initial deposition of fibrin. , 1987, Thrombosis research.

[37]  C. Korninger,et al.  Studies on the Specific Fibrinolytic Effect of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Blood and in Various Animal Species in Vitro , 1981, Thrombosis and Haemostasis.